drugset / Trial / NCT00406497

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation

NCT00406497

Phase 2 Completed 24 enrolled Sirion Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this phase 2 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of postoperative inflammation.

Timeline

Start
2003-04
Primary completion
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Difluprednate Small molecule 0.05 %

Indications

No indication recorded.